14 subscribers
ออฟไลน์ด้วยแอป Player FM !
AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer
Manage episode 460539024 series 1256601
SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium from the BIG 2-04 MRC SUPREMO international phase three randomized controlled trial.
At the conference Ian Kunkler MA, MB, BChir, Professor at Edinburgh Cancer Centre in the Western General Hospital, University of Edinburgh, Scotland UK, told the conference that after investigating the impact of adjuvant chest wall irradiation following mastectomy and axillary surgical staging in patients with operable breast cancer at a defined intermediate-risk of loco-regional recurrence the study had found no benefit.
The trial indicated with high precision that chest wall irradiation following mastectomy in patients with one to three positive nodes, or with node-negative breast cancer having other risk factors, had no impact on overall survival, and a clinically insignificant impact on chest wall recurrence.
After the conference, Kunkler discussed the findings with the Audio Journal of Oncology’s correspondent, Peter Goodwin:
PODCAST: Ian Kunkler in conversation with Peter Goodwin
SABCS 2024 Abstract GS2-03:
Kunkler I et al. “Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators”
https://sabcs.org/Portals/0/Documents/Embargoed/GS2-03%20Embargoed.pdf?ver=kXWlS2Nrc-7_KvwLiqBR1A%3D%3D
Comment
Kunkler I et al. Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigation. Abstract GS2-03. SABCS, 10-13 December, 2024.
51 ตอน
Manage episode 460539024 series 1256601
SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium from the BIG 2-04 MRC SUPREMO international phase three randomized controlled trial.
At the conference Ian Kunkler MA, MB, BChir, Professor at Edinburgh Cancer Centre in the Western General Hospital, University of Edinburgh, Scotland UK, told the conference that after investigating the impact of adjuvant chest wall irradiation following mastectomy and axillary surgical staging in patients with operable breast cancer at a defined intermediate-risk of loco-regional recurrence the study had found no benefit.
The trial indicated with high precision that chest wall irradiation following mastectomy in patients with one to three positive nodes, or with node-negative breast cancer having other risk factors, had no impact on overall survival, and a clinically insignificant impact on chest wall recurrence.
After the conference, Kunkler discussed the findings with the Audio Journal of Oncology’s correspondent, Peter Goodwin:
PODCAST: Ian Kunkler in conversation with Peter Goodwin
SABCS 2024 Abstract GS2-03:
Kunkler I et al. “Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators”
https://sabcs.org/Portals/0/Documents/Embargoed/GS2-03%20Embargoed.pdf?ver=kXWlS2Nrc-7_KvwLiqBR1A%3D%3D
Comment
Kunkler I et al. Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigation. Abstract GS2-03. SABCS, 10-13 December, 2024.
51 ตอน
ทุกตอน
×1 AUDIO JOURNAL OF ONCOLOGY: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS 13:47
1 AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer 15:27
1 AUDIO JOURNAL OF ONCOLOGY: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation 12:28
1 Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia 13:07
1 Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia 7:26
1 Low Rates of Early Detection Drive Excess Breast Cancer Mortality in Underserved Communities 24:31
1 AUDIO JOURNAL OF ONCOLOGY—Options Identified for Chemotherapy Intensity Reduction in Acute Lymphoblastic Leukemia 13:34
1 AUDIO JOURNAL OF ONCOLOGY—Don’t Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia 15:06
1 AUDIO JOURNAL OF ONCOLOGY—Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma 16:28
1 AUDIO JOURNAL OF ONCOLOGY—Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma 20:54
1 AUDIO JOURNAL OF ONCOLOGY—High Response Rates in Lung Cancer from Next Generation ROS1 Inhibitor 12:07
1 AUDIO JOURNAL OF ONCOLOGY—ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy 13:59
1 AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study 10:16
1 AUDIO JOURNAL OF ONCOLOGY—New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma 17:40
ขอต้อนรับสู่ Player FM!
Player FM กำลังหาเว็บ